Literature DB >> 30232552

Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas.

Zhenying Lin1, Luanhong Wang2, Guang Huang3, Wenyan Wang1, Han Lin4.   

Abstract

PURPOSE: We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1α (HIF-1α).
METHODS: Hemangioma tissue was isolated from an infant patient and implanted into nude mice to establish a hemangioma model. Twenty-four hemangioma-model nude mice were divided into two groups including a control group (saline, by gastrogavage) and an experimental group (propranolol, by gastrogavage). The hemangioma-model nude mice were euthanized and tumors were removed at 30 and 50 days (before and after treatment). HE staining was used to observe the histopathological changes, and western blot and quantitative real-time PCR were used to describe levels of protein and mRNA expression of PI3K, AKT, and HIF-1α.
RESULTS: Propranolol treatment decreased tumor size as compared to the control group. Protein and mRNA expression levels of PI3K, AKT, and HIF-1α were lower in the experimental group at day 50 compared to the control group at day 50 and the experimental group at day 30 (p < 0.05).
CONCLUSION: Propranolol can promote regression of infantile hemangiomas, which may be related to the inhibition of PI3K, AKT, and HIF-1α activity.

Entities:  

Keywords:  AKT; HIF-1α; Hemangioma; PI3K; Propranolol

Mesh:

Substances:

Year:  2018        PMID: 30232552     DOI: 10.1007/s00383-018-4347-9

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  12 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 2.  Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.

Authors:  Shoshana Greenberger; Joyce Bischoff
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Diagnosis and Management of Infantile Hemangioma: Executive Summary.

Authors:  David H Darrow; Arin K Greene; Anthony J Mancini; Amy J Nopper
Journal:  Pediatrics       Date:  2015-10       Impact factor: 7.124

Review 4.  Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation.

Authors:  M A Krasilnikov
Journal:  Biochemistry (Mosc)       Date:  2000-01       Impact factor: 2.487

5.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

6.  Beta-blockers for the treatment of problematic hemangiomas.

Authors:  Vishal K Sharma; Frankie Og Fraulin; Danielle O Dumestre; Lori Walker; A Robertson Harrop
Journal:  Can J Plast Surg       Date:  2013

Review 7.  Hypoxia, hormones, and endothelial progenitor cells in hemangioma.

Authors:  Edward I Chang; Eric I Chang; Hariharan Thangarajah; Cynthia Hamou; Geoffrey C Gurtner
Journal:  Lymphat Res Biol       Date:  2007       Impact factor: 2.589

Review 8.  [Regulation of the Hypoxia-Inducible Factor-1alpha (HIF-1alpha): a breath of fresh air in hypoxia research].

Authors:  Mélanie Berta; Christiane Brahimi-Horn; Jacques Pouyssegur
Journal:  J Soc Biol       Date:  2004

Review 9.  HIF-1α pathway: role, regulation and intervention for cancer therapy.

Authors:  Georgina N Masoud; Wei Li
Journal:  Acta Pharm Sin B       Date:  2015-06-06       Impact factor: 11.413

10.  Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms.

Authors:  Y Z Chen; N Bai; J H Bi; X W Liu; G Q Xu; L F Zhang; X Q Li; R Huo
Journal:  Braz J Med Biol Res       Date:  2017-10-02       Impact factor: 2.590

View more
  5 in total

1.  CircATP5SL promotes infantile haemangiomas progression via IGF1R regulation by targeting miR-873-5p.

Authors:  Zhiqiang Wei; Xiaoqi Yuan; Qi Ding; Yanan Xu; Lu Hong; Jianhua Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Junbo Qiao; Junjie Lin; Dexin Zhang; Junhua Li; Changkuan Chen; Hongye Yu; Xiaodi Li; Bin Fang
Journal:  Front Pharmacol       Date:  2020-10-08       Impact factor: 5.810

3.  Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.

Authors:  L E Anselmino; M V Baglioni; F Malizia; N Cesatti Laluce; C Borini Etichetti; V L Martínez Marignac; V Rozados; O G Scharovsky; J Girardini; M J Rico; M Menacho Márquez
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

4.  Clinical and genetic analyses of patients with lateralized overgrowth.

Authors:  Yoon-Myung Kim; Yena Lee; Yunha Choi; In Hee Choi; Sun Hee Heo; Jung Min Choi; Hyo-Sang Do; Ja-Hyun Jang; Mi-Sun Yum; Han-Wook Yoo; Beom Hee Lee
Journal:  BMC Med Genomics       Date:  2022-09-30       Impact factor: 3.622

5.  Real-time optical imaging of the hypoxic status in hemangioma endothelial cells during propranolol therapy.

Authors:  Yue Wu; Xiaojuan Yang; Mingrui Zhai; Yi Chen; Xiaoya Lu; Jiandong Ju; Huanqing Zhang; Guanduo Wang; Zhe Zhang; Baocun Zhu; Xuan Wang; Zhanwei Chen; Shengyun Huang
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.